Maze Therapeutics (MAZE) Misses Q2 EPS by 19c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St set for higher open as Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts MAZE Hot Sheet
Join SI Premium – FREE
Maze Therapeutics (NASDAQ: MAZE) reported Q2 EPS of ($0.76), $0.19 worse than the analyst estimate of ($0.57).
For earnings history and earnings-related data on Maze Therapeutics (MAZE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Uber Q3 profit, revenue beat estimates as gross bookings jump 20%
- Truist Securities Reiterates Buy Rating on Curbline Properties Corp (CURB)
- Datadog stock tumbles 19% despite earnings beat
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
